Drug Companies Target Patients

By THE ASSOCIATED PRESS

Filed at 5:04 p.m. ET

TV viewers are right if they are feeling barraged by commercials for the likes of Vioxx, Prilosec, Claritin and Viagra: Drug company advertising aimed at ordinary people instead of doctors tripled in the United States between 1996 and 2000 to nearly $2.5 billion a year.

Advertisements targeting consumers account for 15 percent of U.S. spending to promote medications, up from almost 9 percent in 1996, a study found.

Spending that targets doctors -- including visits from sales representatives, free samples and medical journal ads -- slipped from 91 percent to 84 percent during the same period, according to researchers at Harvard University and the Massachusetts Institute of Technology.

They analyzed data on media advertising and sales of individual drugs, examining trends since 1996, the year before the Food and Drug Administration issued rules for television ads on prescription drugs.

The study appears in Thursday's New England Journal of Medicine.

Critics such as Dr. Sidney Wolfe of Public Citizen Health Research Group argue that drug ads aimed at ordinary people encourage use of expensive, sometimes unnecessary medicines, appeal to patients' emotions, undermine the doctor-patient relationship and rarely tell patients about the drugs' success rate, alternative treatments and other key information.

The pharmaceutical industry argues the ads inform and empower consumers, prompt many to see their doctor about an untreated health problem and nudge others to take their prescription drugs more faithfully.

The researchers found the biggest jump has been in TV commercials, with a seven-fold increase in spending -- from $220 million to $1.6 billion -- between 1996 and 2000.

Sixty percent of the print and broadcast ads were for just 20 medications, including the arthritis drugs Vioxx and Celebrex, the ulcer drug Prilosec, Viagra for impotence and the allergy drugs Claritin, Allegra and Zyrtec.

Total spending on prescription drug promotion grew about 70 percent, from about $9.2 billion in 1996 to $15.7 billion in 2000, the same rate of growth as drug sales had during that period.

^------

On the Net: http://www.nejm.com

http://www.hsph.harvard.edu

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.